Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21/Matrix-M and ME-TRAP Malaria Challenge Study
NCT03947190Phase 2Terminated
- Sponsor
- University of Oxford
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Viral Vector Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of R21/Matrix-M and ChAd63/MVA ME-TRAP in Falciparum malaria (PF) (4 arms), sponsored by University of Oxford. Primary endpoints: Occurrence of solicited local and systemic reactogenicity signs and symptoms, and unsolicited adverse events, Occurrence of P. falciparum parasitemia assessed by PCR and 1 more. Started Aug 2022; status: terminated.
02
Drugs
R21/Matrix-MChAd63/MVA ME-TRAP
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on NCT03947190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947190.